Horizons in Cancer Research. Volume 69

$290.00

Hiroto S. Watanabe (Editor)

Series: Horizons in Cancer Research
BISAC: MED062000

Horizons in Cancer Research. Volume 69 opens with a discussion on hypothetical mechanisms of the induction of NKreg cells in cancer and possible approaches to their abrogation, suggesting that for profound understanding of the problem of NKregs in the context of future target cancer immunotherapy, extensive clinical observations of NKreg cells should be carried out. Afterwards, the authors focus on the cell surface molecules in adult T-cell leukemia/lymphoma (ATL) cells, the function of matricellular proteins, particularly OPN, and their potential as targets for ATL immunotherapy. Later, the book demonstrates dual distinct functional roles of widespread cancerous immunoglobulins among cancer cells for the potential applications of RP215 in therapeutic treatments of many human cancers. RP215-linked chimeric antigen receptor (CAR)-T cell therapy technology has been applied in anti-cancer treatments through a series of CAR construction and validations by cytotoxic cell killing and cytokine activity release assays. Next, the authors present a new approach to describing, analyzing and understanding the process of dying in cancer patients based on the assumption that there are four tracks along which dying proceeds: the track focused on the medical-diagnostic aspects of the disease, the track referring to the physical aspects of the disease, the track defined by the psychological aspects of the disease and the track describing the coping- determined aspects of dying. In a separate study, examples of cases using a flexible, inflatable multi-channel applicator for the treatment of primary and recurrent gynecologic cancer, as well as treatment with Syed interstitial brachytherapy are presented. The examples are intended to emphasize the different characteristics of patient’s anatomy and tumors that guide the selection of a particular applicator and brachytherapy technique. Afterwards, the role of emodin in cancer prevention is discussed. Emodin possesses a broad spectrum of pharmacological, anticancer, anti-inflammatory, antioxidant and antimicrobial activities.

Table of Contents

Table of Contents

Preface

Chapter 1. Regulatory NK Cells: A Potentially Negative Role in Cancer
(Nikolai N. Belyaev, DrSc., Yekaterina O. Ostapchuk, PhD, and Yuliya V. Perfilyeva, PhD, Saint-Petersburg Pasteur Institute, Saint-Petersburg, Russia, and others)

Chapter 2. Antibody-Based Immunotherapy in Adult T-Cell Leukemia/Lymphoma
(Naoyoshi Maeda and Katsumi Maenaka, Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo, Japan, and others)

Chapter 3. Cancerous Immunoglobulins and Potential Clinical Applications
(Gregory Lee, Center for Reproductive Health, University of British Columbia, Vancouver, BC, Canada)

Chapter 4. Dying from Cancer: The Four Tracks
(Shulamith Kreitler, School of Psychological Sciences,Tel-Aviv University and Psychooncology Research Center, Sheba Medicl Center, Tel Hashomer, Israel)

Chapter 5. Brachytherapy Techniques for the Definitive Treatment of Vaginal Cancer
(Leah M. Katz, Wesley J. Talcott, Penelope N. Halkiadakis1 and Stella C. Lymberis, Department of Radiation Oncology, New York University, NYU Langone Health, New York, NY, USA, and others)

Chapter 6. Claudins Role in Oncogenesis: An Update with a Look at the Role of Claudins in Oral Squamous Cell Cancer
(Norah AlRohaimi, Saed Marmash, Wael Al-Kattan, MD, and Abderrahman Ouban, MD, Alfaisal University College of Medicine, Riyadh, Kingdom of Saudi Arabia)

Chapter 7. The Role of Emodin in Cancer Prevention
(Pushpendra Singh, Pushpendu Kundu and Ravindra Kumar, Centre for Biosciences, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, Punjab, India, and others)

Index

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!